Showing results 1 to 20 of 918
next >
| Preview | Issue Date | Title | Author(s) |
| 2023 | In vitro and in vivo evaluation of diethyldithiocarbamate with copper ions and its liposomal formulation for the treatment of Staphylococcus aureus and Staphylococcus epidermidis biofilms | Kaul, L.; Abdo, A.I.; Coenye, T.; Swift, S.; Zannettino, A.; Süss, R.; Richter, K. |
| 2023 | Evaluation of Uptake of COVID-19 Temporary Allied Health Services for Residential Aged Care in Australia | Caughey, G.E.; Collier, L.; Cations, M.; Wesselingh, S.; Inacio, M.C. |
| 2022 | Recent breakthroughs and future directions in drugging aquaporins | Salman, M.M.; Kitchen, P.; Yool, A.J.; Bill, R.M. |
| 2022 | Examining the cost and impact of dosing fees among clients in opioid agonist treatment: results from a cross-sectional survey of Australian treatment clients | Zahra, E.; Chen, R.; Nielsen, S.; Tran, A.D.; Santo, T.; Degenhardt, L.; Farrell, M.; Byrne, J.; Ali, R.; Larance, B. |
| 2022 | Review article: the future of microbiome-based therapeutics | Gulliver, E.L.; Young, R.B.; Chonwerawong, M.; D'Adamo, G.L.; Thomason, T.; Widdop, J.T.; Rutten, E.L.; Rossetto Marcelino, V.; Bryant, R.V.; Costello, S.P.; O'Brien, C.L.; Hold, G.L.; Giles, E.M.; Forster, S.C. |
| 2022 | The Extracellular Molecular Chaperone Clusterin Inhibits Amyloid Fibril Formation and Suppresses Cytotoxicity Associated with Semen-Derived Enhancer of Virus Infection (SEVI) | Elias, A.K.; Wilson, M.R.; Carver, J.A.; Musgrave, I.F. |
| 2022 | Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB® | Staudacher, A.H.; Liapis, V.; Wittwer, N.L.; Tieu, W.; Lam, H.C.; Leusen, J.; Brown, M.P. |
| 2022 | Primary and Secondary Care Related Quality Indicators for Dementia Care Among Australian Aged Care Users: National Trends, Risk Factors, and Variation | Rahja, M.; Air, T.; Ahern, S.; Ward, S.A.; Caughey, G.E.; Sluggett, J.K.; Cations, M.; Lin, X.; Wallis, K.; Crotty, M.; Inacio, M.C. |
| 2021 | Endocannabinoids in bladder sensory mechanisms in health and diseases | Christie, S.; Brookes, S.; Zagorodnyuk, V. |
| 2021 | Treatment of cystic fibrosis: from gene- to cell-based therapies | Allan, K.M.; Farrow, N.; Donnelley, M.; Jaffe, A.; Waters, S.A. |
| 2021 | Are sarcopenia and cognitive dysfunction comorbid after stroke in the context of brain–muscle crosstalk? | Sui, S.X.; Hordacre, B.; Pasco, J.A. |
| 2021 | Emerging benefits and drawbacks of α₂-adrenoceptor agonists in the management of sepsis and critical illness | Lankadeva, Y.R.; Shehabi, Y.; Deane, A.M.; Plummer, M.P.; Bellomo, R.; May, C.N. |
| 2021 | Structure activity refinement of phenylsulfonyl piperazines as antimalarials that block erythrocytic invasion | Nguyen, W.; Dans, M.G.; Ngo, A.; Gancheva, M.R.; Romeo, O.; Duffy, S.; de Koning-Ward, T.F.; Lowes, K.N.; Sabroux, H.J.; Avery, V.M.; Wilson, D.W.; Gilson, P.R.; Sleebs, B.E. |
| 2021 | Residential medication management reviews in Australian residential aged care facilities | Sluggett, J.K.; Bell, J.S.; Lang, C.; Corlis, M.; Whitehead, C.; Wesselingh, S.L.; Inacio, M.C. |
| 2021 | Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and HLA-B genotypes and phenytoin dosing: 2020 update | Karnes, J.H.; Rettie, A.E.; Somogyi, A.A.; Huddart, R.; Fohner, A.E.; Formea, C.M.; Lee, M.T.M.; Llerena, A.; Whirl-Carrillo, M.; Klein, T.E.; Phillips, E.J.; Mintzer, S.; Gaedigk, A.; Caudle, K.E.; Callaghan, J.T. |
| 2021 | Investigation of genetic loci shared between bipolar disorder and risk-taking propensity: potential implications for pharmacological interventions | Pisanu, C.; Congiu, D.; Severino, G.; Ardau, R.; Chillotti, C.; Del Zompo, M.; Baune, B.T.; Squassina, A. |
| 2021 | The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study | Bharat, C.; Larney, S.; Barbieri, S.; Dobbins, T.; Jones, N.R.; Hickman, M.; Gisev, N.; Ali, R.; Degenhardt, L. |
| 2021 | Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy | Crews, K.R.; Monte, A.A.; Huddart, R.; Caudle, K.E.; Kharasch, E.D.; Gaedigk, A.; Dunnenberger, H.M.; Leeder, J.S.; Callaghan, J.T.; Samer, C.F.; Klein, T.E.; Haidar, C.E.; Van Driest, S.L.; Ruano, G.; Sangkuhl, K.; Cavallari, L.H.; Müller, D.J.; Prows, C.A.; Nagy, M.; Somogyi, A.A.; et al. |
| 2021 | Emerging therapeutic applications for fumarates | Hoogendoorn, A.; Avery, T.D.; Li, J.; Bursill, C.; Abell, A.; Grace, P.M. |
| 2021 | In vitro synergistic activity of NCL195 in combination with colistin against Gram-negative bacterial pathogens | Nguyen, H.T.; Venter, H.; Veltman, T.; Williams, R.; Anne O'Donovan, L.; Russell, C.C.; McCluskey, A.; Page, S.W.; Ogunniyi, A.D.; Trott, D.J. |
